Missing one or more active (white) pills could result in reduced effectiveness for contraception, with the possibility of an unplanned pregnancy. As of August 27, 2013, there had been no adverse reactions reported to Mylan Pharmaceuticals.
Products affected: Freya-28 (Lots: 3739F001B & 3739F002B)
Packages of Freya-28 should have three rows of active (white) pills and one row of placebo (green) pills.
The company has informed Health Canada that its other birth control product, Freya-21 is not impacted. Packages of Freya-21 should only have 21 white (active) pills.
Health Canada will continue to monitor the situation and update Canadians and health care practitioners should new information or products, be identified.
No comments:
Post a Comment